Cataract, Refractive, Global Ophthalmology, Practice Development, Society News, Inside ESCRS
ESCRS Accepting Applications for Peter Barry Fellowship
Applications are now open for the 2025 Peter Barry Fellowship, which honours the immense contributions to ophthalmology and ESCRS by the late Peter Barry.
The Fellowship includes a stipend of €60,000 to allow a trainee to work abroad at a centre of excellence for clinical experience or research in the field of cataract and refractive surgery, anywhere in the world, for one year. Applicants must be a European trainee ophthalmologist, 40 years of age or younger on the closing date for applications (2 March 2025), and an ESCRS member by the time of starting the Fellowship.
Eligible applications will be evaluated by an expert panel against the proposed research importance assessment criteria. Selected applicants will then be invited for an interview with the ESCRS Peter Barry Fellowship Committee.
The Fellowship recipient will be announced at the 2025 ESCRS Annual Congress, with the Fellowship starting the following year.
Tags: cataract surgery, refractive surgery, education, ESCRS education, 2025 Peter Barry Fellowship, young ophthalmologists, YOs, research, continued education, applications, ESCRS members
Latest Articles
Committing to a More Equitable Ophthalmology
Charity Committee enhances ESCRS’s reputation as a socially responsible society.
Virtual Community Unites Ukrainian Eye Specialists
Microlearning platform proves vital to saving eyes and lives in areas of conflict.
ESCRS Survey Shifts Industry Dial
Annual survey reveals trends and issues regarding the digital OR.
Always Measure the Epithelium!
Epithelium thickness mapping key to better refractive outcomes.
Advancing Vision Research
National Eye Institute initiatives encourage AI-based innovations and data interoperability.
Best Candidates for Phakic EDOF IOLs?
Patient profile suggests limits for phakic EDOF approach.
Knowing Iris Repair: Iris Repair with Prosthetic Devices
New devices on the market expand available options when iris tissue is insufficient.
Targeting the Kallikrein-Kinin System to Treat DME
Novel oral plasma kallikrein inhibitor shows promise in early clinical trial.
Faricimab VOYAGER Study
Real-world experience with faricimab for treatment-naïve nAMD and DME is underway.